| Robert Balk, MD | |
|
1725 W Harrison St, Pob 054, Chicago, IL 60612-3841 | |
| (312) 942-5871 | |
| Not Available |
| Full Name | Robert Balk |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 46 Years |
| Location | 1725 W Harrison St, Chicago, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134173503 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | (Illinois) | Primary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Rush University Medical Center | Chicago, IL | Hospital |
| Rush Oak Park Hospital | Oak park, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rush University Medical Center | 5496658874 | 1007 |
News Archive
Sudden unexpected death in epilepsy (SUDEP) is concerning and many—even those with seizure disorders—may not be aware of this condition. New research published in Epilepsia, a journal published by Wiley on behalf of the International League Against Epilepsy (ILAE), reports that 76% of caregivers are more likely to have heard of SUDEP compared with 65% of patients with epilepsy.
To generate swarms of new viral particles, a virus hijacks a cell into producing masses of self-assembling cages that are then loaded with the genetic blueprint for the next infection.
In 2004, Pfizer, the world's largest drug company, agreed to plead guilty and pay more than $430 million to settle charges it had illegally marketed the epilepsy drug Neurontin for unapproved uses.
Natera (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, and Biopticka Laborator, one of the largest and most well-established laboratories in the Czech Republic, today announced a Constellation™ technology transfer licensing agreement that enables Biopticka Laborator to leverage Natera's proprietary single nucleotide polymorphism-based (SNP) technology to screen for fetal aneuploidies.
› Verified 1 days ago
| Entity Name | Rush University Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023061611 PECOS PAC ID: 8729989942 Enrollment ID: O20040120000209 |
News Archive
Sudden unexpected death in epilepsy (SUDEP) is concerning and many—even those with seizure disorders—may not be aware of this condition. New research published in Epilepsia, a journal published by Wiley on behalf of the International League Against Epilepsy (ILAE), reports that 76% of caregivers are more likely to have heard of SUDEP compared with 65% of patients with epilepsy.
To generate swarms of new viral particles, a virus hijacks a cell into producing masses of self-assembling cages that are then loaded with the genetic blueprint for the next infection.
In 2004, Pfizer, the world's largest drug company, agreed to plead guilty and pay more than $430 million to settle charges it had illegally marketed the epilepsy drug Neurontin for unapproved uses.
Natera (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, and Biopticka Laborator, one of the largest and most well-established laboratories in the Czech Republic, today announced a Constellation™ technology transfer licensing agreement that enables Biopticka Laborator to leverage Natera's proprietary single nucleotide polymorphism-based (SNP) technology to screen for fetal aneuploidies.
› Verified 1 days ago
| Entity Name | Rush University Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093819542 PECOS PAC ID: 5496658874 Enrollment ID: O20040202000228 |
News Archive
Sudden unexpected death in epilepsy (SUDEP) is concerning and many—even those with seizure disorders—may not be aware of this condition. New research published in Epilepsia, a journal published by Wiley on behalf of the International League Against Epilepsy (ILAE), reports that 76% of caregivers are more likely to have heard of SUDEP compared with 65% of patients with epilepsy.
To generate swarms of new viral particles, a virus hijacks a cell into producing masses of self-assembling cages that are then loaded with the genetic blueprint for the next infection.
In 2004, Pfizer, the world's largest drug company, agreed to plead guilty and pay more than $430 million to settle charges it had illegally marketed the epilepsy drug Neurontin for unapproved uses.
Natera (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, and Biopticka Laborator, one of the largest and most well-established laboratories in the Czech Republic, today announced a Constellation™ technology transfer licensing agreement that enables Biopticka Laborator to leverage Natera's proprietary single nucleotide polymorphism-based (SNP) technology to screen for fetal aneuploidies.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert Balk, MD 1725 W Harrison St, Pob 054, Chicago, IL 60612-3841 Ph: (312) 942-5871 | Robert Balk, MD 1725 W Harrison St, Pob 054, Chicago, IL 60612-3841 Ph: (312) 942-5871 |
News Archive
Sudden unexpected death in epilepsy (SUDEP) is concerning and many—even those with seizure disorders—may not be aware of this condition. New research published in Epilepsia, a journal published by Wiley on behalf of the International League Against Epilepsy (ILAE), reports that 76% of caregivers are more likely to have heard of SUDEP compared with 65% of patients with epilepsy.
To generate swarms of new viral particles, a virus hijacks a cell into producing masses of self-assembling cages that are then loaded with the genetic blueprint for the next infection.
In 2004, Pfizer, the world's largest drug company, agreed to plead guilty and pay more than $430 million to settle charges it had illegally marketed the epilepsy drug Neurontin for unapproved uses.
Natera (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, and Biopticka Laborator, one of the largest and most well-established laboratories in the Czech Republic, today announced a Constellation™ technology transfer licensing agreement that enables Biopticka Laborator to leverage Natera's proprietary single nucleotide polymorphism-based (SNP) technology to screen for fetal aneuploidies.
› Verified 1 days ago
Dr. Sorin C Danciu, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3134 N Clark St, Chicago, IL 60657 Phone: 773-880-9722 | |
Anoopa A. Koshy, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 259 E Erie St Ste 2200, Chicago, IL 60611 Phone: 312-926-6000 | |
William Edmond Gerardi, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 3730 N Lake Shore Dr, Apartment 2a, Chicago, IL 60613 Phone: 773-244-3060 | |
Suparna Dutta, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1700 W Van Buren St, Suite 500, Chicago, IL 60612 Phone: 312-942-4200 Fax: 312-942-3568 | |
Alexandra Dumitrescu, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 5841 S Maryland Ave, Chicago, IL 60637 Phone: 888-824-0200 | |
Dr. Mitesh Mahesh Kabadi, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1725 W Harrison St Ste 1159, Chicago, IL 60612 Phone: 312-942-5020 | |
Dr. Marta Batus, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1725 W Harrison St, Suite 809, Chicago, IL 60612 Phone: 312-563-2487 Fax: 312-942-3192 |